ATE68702T1 - Zusammensetzungen zur behandlung von viralen und krebsartigen hautverletzungen und dergleichen. - Google Patents

Zusammensetzungen zur behandlung von viralen und krebsartigen hautverletzungen und dergleichen.

Info

Publication number
ATE68702T1
ATE68702T1 AT87102198T AT87102198T ATE68702T1 AT E68702 T1 ATE68702 T1 AT E68702T1 AT 87102198 T AT87102198 T AT 87102198T AT 87102198 T AT87102198 T AT 87102198T AT E68702 T1 ATE68702 T1 AT E68702T1
Authority
AT
Austria
Prior art keywords
viral
compositions
treatment
skin
cancerus
Prior art date
Application number
AT87102198T
Other languages
English (en)
Inventor
Maxwell M Powell
Original Assignee
Exovir Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exovir Inc filed Critical Exovir Inc
Application granted granted Critical
Publication of ATE68702T1 publication Critical patent/ATE68702T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60D—VEHICLE CONNECTIONS
    • B60D1/00—Traction couplings; Hitches; Draw-gear; Towing devices
    • B60D1/58—Auxiliary devices
    • B60D1/66—Props
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Transportation (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT87102198T 1986-02-18 1987-02-17 Zusammensetzungen zur behandlung von viralen und krebsartigen hautverletzungen und dergleichen. ATE68702T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/830,662 US4822605A (en) 1986-02-18 1986-02-18 Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
EP87102198A EP0233629B1 (de) 1986-02-18 1987-02-17 Zusammensetzungen zur Behandlung von viralen und krebsartigen Hautverletzungen und dergleichen

Publications (1)

Publication Number Publication Date
ATE68702T1 true ATE68702T1 (de) 1991-11-15

Family

ID=25257431

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87102198T ATE68702T1 (de) 1986-02-18 1987-02-17 Zusammensetzungen zur behandlung von viralen und krebsartigen hautverletzungen und dergleichen.

Country Status (10)

Country Link
US (1) US4822605A (de)
EP (1) EP0233629B1 (de)
JP (1) JPS62240627A (de)
AT (1) ATE68702T1 (de)
AU (1) AU598232B2 (de)
CA (1) CA1297006C (de)
DE (1) DE3773953D1 (de)
DK (1) DK82287A (de)
IL (1) IL82351A (de)
ZA (1) ZA87702B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
ZA873743B (en) * 1986-05-27 1987-11-25 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
US6060459A (en) * 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US5342613A (en) * 1988-12-27 1994-08-30 Health Research Inc. Pharmaceutical compositions and use thereof in the treatment of psoriasis
ES2034790T3 (es) * 1989-04-11 1993-04-01 Boehringer Ingelheim International Gmbh Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas.
US5028421A (en) * 1989-05-25 1991-07-02 Embrex, Inc. Method of treating birds
CA2067821A1 (en) * 1989-10-24 1991-04-25 Cetus Oncology Corporation Infective drug delivery system using recombinant retroviral vectors
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
JPH06501456A (ja) * 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
US5082472A (en) * 1990-11-05 1992-01-21 Mallouk Robert S Composite membrane for facilitated transport processes
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
US5547661A (en) * 1994-02-22 1996-08-20 Helene Curtis, Inc. Antiperspirant deodorant compositions
IL112649A (en) * 1994-02-22 1999-12-22 Curtis Helene Ind Inc Topically effective compositions for application to the skin or hair
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US5547551A (en) * 1995-03-15 1996-08-20 W. L. Gore & Associates, Inc. Ultra-thin integral composite membrane
USRE37307E1 (en) 1994-11-14 2001-08-07 W. L. Gore & Associates, Inc. Ultra-thin integral composite membrane
US5599614A (en) * 1995-03-15 1997-02-04 W. L. Gore & Associates, Inc. Integral composite membrane
USRE37701E1 (en) * 1994-11-14 2002-05-14 W. L. Gore & Associates, Inc. Integral composite membrane
US6254978B1 (en) 1994-11-14 2001-07-03 W. L. Gore & Associates, Inc. Ultra-thin integral composite membrane
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
ES2264145T3 (es) * 1995-11-30 2006-12-16 The Board Of Regents, The University Of Texas System Metodos y composiciones para el tratamiento de cancer.
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
WO1998041230A1 (fr) * 1997-03-14 1998-09-24 Snow Brand Milk Products Co., Ltd. Agent preventif et/ou curatif de la cachexie
US6130175A (en) * 1997-04-29 2000-10-10 Gore Enterprise Holdings, Inc. Integral multi-layered ion-exchange composite membranes
US6638659B1 (en) 1999-04-30 2003-10-28 University Of Connecticut Membrane electrode assemblies using ionic composite membranes
US6211243B1 (en) 1999-09-22 2001-04-03 B. Ron Johnson Methods for treating cold sores with anti-infective compositions
US6759434B2 (en) 1999-09-22 2004-07-06 B. Ron Johnson Anti-infective compositions, methods and systems for treating disordered tissue
US8173709B2 (en) * 1999-09-22 2012-05-08 Quadex Pharmaceuticals, Llc Anti-infective methods for treating pathogen-induced disordered tissues
US6410597B1 (en) * 2000-02-25 2002-06-25 Virginia Commonwealth University Hydroxyalkyl amide analogs of ceramide
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US6613203B1 (en) 2001-09-10 2003-09-02 Gore Enterprise Holdings Ion conducting membrane having high hardness and dimensional stability
US6668753B2 (en) 2002-02-13 2003-12-30 Embrex, Inc. Methods and apparatus for delivering fluid to egg injection devices
US6860225B2 (en) * 2002-05-06 2005-03-01 Embrex, Inc. Methods and apparatus for identifying live eggs by detecting embryo heart rate and/or motion
US7373561B2 (en) * 2002-10-29 2008-05-13 Broadcom Corporation Integrated packet bit error rate tester for 10G SERDES
CA2508375C (en) * 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US20050100601A1 (en) * 2003-11-07 2005-05-12 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
US20090232748A1 (en) * 2003-11-07 2009-09-17 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US9023863B2 (en) 2006-07-14 2015-05-05 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
SG154441A1 (en) * 2006-10-20 2009-08-28 Biogen Idec Inc Treatment of demyelinating disorders
WO2008070317A2 (en) * 2006-11-29 2008-06-12 Redox Pharmaceutical Corporation A method for the treatment of psoriasis
US8741954B2 (en) * 2007-02-21 2014-06-03 Viratox, L.L.C. Synergistic enhancement of calcium propionate
EP2474066A1 (de) 2009-09-03 2012-07-11 E. I. du Pont de Nemours and Company Verbesserte katalysatorbeschichtete membranen mit verbundstoff, dünne membrannen und dünne kathoden zur verwendung für direktmethanolbrennstoffzellen
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
EA201990140A1 (ru) 2016-06-28 2019-07-31 Мехмет Невзат Писак Поверхностно-активные вещества для лечения инфекций кожи, вызываемых содержащими двухцепочечную днк вирусами семейств herpesviridae или papillomaviridae

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020183A (en) * 1974-12-03 1977-04-26 Ortho Pharmaceutical Corporation Nonionic surface active anti-herpes simplex viral agents
US4480032A (en) * 1980-11-13 1984-10-30 Yabrov Alexander A Natural mixture of Type I and Type II interferons
DE3117934A1 (de) * 1981-05-06 1982-12-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neues peptid, verfahren zu seiner gewinnung und dieses enthaltendes arzneimittel
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
EP0305551A3 (de) * 1981-10-13 1990-01-10 Exovir, Inc. Pharmazeutische Zusammensetzungen zur topischen Anwendung
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
IL71954A0 (en) * 1983-06-01 1984-09-30 Genentech Inc Gamma interferon-lymphotoxin synergism
JPS6019719A (ja) * 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd 抗腫瘍活性を有する蛋白質
EP0149551A3 (de) * 1984-01-16 1987-09-23 Genentech, Inc. Synergistische Gamma-Interferon-Interleukin-2-Zusammensetzungen und Verfahren zur Herstellung desselben
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
EP0256119A4 (de) * 1986-02-10 1988-08-23 Liposome Technology Inc Liposomenverabreichungssystem mit geregelter verabreichung.

Also Published As

Publication number Publication date
AU598232B2 (en) 1990-06-21
US4822605A (en) 1989-04-18
DE3773953D1 (de) 1991-11-28
JPS62240627A (ja) 1987-10-21
ZA87702B (en) 1987-09-30
AU6879087A (en) 1987-08-20
EP0233629B1 (de) 1991-10-23
IL82351A (en) 1990-12-23
EP0233629A1 (de) 1987-08-26
CA1297006C (en) 1992-03-10
DK82287D0 (da) 1987-02-18
DK82287A (da) 1987-08-19

Similar Documents

Publication Publication Date Title
ATE68702T1 (de) Zusammensetzungen zur behandlung von viralen und krebsartigen hautverletzungen und dergleichen.
YU47968B (sh) Postupak za dobivanje faktora nekroze tumora
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
ES2020011A6 (es) Metodo de sintesis de composiciones que comprenden al menos un butano fenolico.
ATE70449T1 (de) Zusammensetzungen von katecholischen butanen mit zink.
DK0668769T3 (da) Egebarkekstrakt-relaterede syntetiske sammensætninger og fremgangsmåde til deres anvendelse
ES2151502T3 (es) Complejos quelato y procedimientos para su obtencion.
ATE67675T1 (de) Kombination von gammainterferonen und antientzuendungsmitteln oder antipyretischen mitteln zur behandlung von krankheiten.
IT8419681A0 (it) Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche.
DK540586A (da) Cardiotonisk virksomme thiazoloner
DE3771584D1 (de) Zusammensetzungen und anwendung von interleukin-2 und/oder interferon-beta und des tumor-necrosis-faktors fuer eine kombinationstherapie oder zur herstellung von arzneimitteln oder formulierungen.
ATE100717T1 (de) Intralaesionale behandlung von basalzellenkarzinoma mittels rekombinanten humanen alpha-interferons.
ATE69551T1 (de) Zusammensetzung zur behandlung von boesartigen tumoren insbesondere bei tieren.
SU688447A1 (ru) Стекло с анионной проводимостью по брому
Kumagai et al. The Realities of Common Rights in Modern Age
ES8802250A1 (es) Un metodo para producir factor de necrosis de tumores.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties